Understanding SARM1 in Heart Disease Linked to Metabolism
Roles of SARM1 NAD hydrolase in metabolic cardiomyopathy
This project looks at how a protein called SARM1 contributes to heart problems in people with metabolic conditions, hoping to find new ways to protect the heart.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oklahoma Medical Research Foundation NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-11110347 on NIH RePORTER |
What this research studies
Our hearts need a molecule called NAD+ to stay healthy, but in conditions like heart failure and metabolic cardiomyopathy, NAD+ levels can drop. While some approaches try to boost NAD+ production, we are exploring a different path: stopping its breakdown. We are focusing on a specific protein, SARM1, which breaks down NAD+ and might play a role in heart damage. By understanding how SARM1 works in the heart, especially in conditions like diabetes, we hope to discover new targets for medicines that can prevent or treat heart disease.
Who could benefit from this research
Good fit: Future patients who could benefit from this research are those experiencing heart problems related to metabolic conditions, such as adult-onset diabetes.
Not a fit: Patients whose heart conditions are not linked to metabolic issues or NAD+ depletion may not directly benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to new medications that protect the heart by preventing NAD+ depletion in patients with metabolic cardiomyopathy.
How similar studies have performed: While boosting NAD+ synthesis has shown promise, the specific role of SARM1 in metabolic cardiomyopathy is a new area of focus for therapeutic development.
Where this research is happening
Oklahoma City, United States
- Oklahoma Medical Research Foundation — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Lee, Chi Fung — Oklahoma Medical Research Foundation
- Study coordinator: Lee, Chi Fung
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.